Mesenchymal Stem Cell Transplantation in MS

Inclusion Criteria

• •1. Inflammatory forms of MS
• •1. Relapsing-remitting MS (RRMS) patients
• •2. Secondary progressive MS (SPMS) patients with continued relapses
• •3. Primary progressive MS (PPMS) patients with enhancing MRI lesions and positive CSF (oligoclonal banding)
• •2. Age 18-50 years
• •3. Disease duration \>= 2 and \>= 10 years
• •4. EDSS 3.0 - 6.5
• •5. Progression, continued relapses or worsening MRI after at least a year of attempted therapy evidenced by:
• •1. Increase of \>= 1 EDSS point (if baseline EDSS \<= 5.0) or 0.5 EDSS points (if baseline EDSS \>= 5.5), or quantifiable, objective evidence of equivalent progression
• •2. \>= 1 moderate-severe relapses in past 18 months
• •3. \>= 1 Gadolinium enhancing lesions (double or triple dose Gadolinium)
• •4. \>= 1 new T2 lesion
• •5. For PPMS only, \>= 1 Gadolinium enhancing lesions
• •6. Has given informed consent to participate in the study.